Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD.
Nataliya Prokopenko BuxbaumGerard SociéGeoffrey R HillKelli Pa MacDonaldVictor TkachevTakanori TeshimaStephanie J LeeJerome RitzStefanie SarantopoulosLeo LuznikDefu ZengSophie PaczesnyPaul J MartinSteven Z PavleticKirk R SchultzBruce R BlazarPublished in: Blood advances (2022)
Chronic GvHD (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of non-relapse mortality and significant morbidity. Tremendous progress has been achieved in both understanding of pathophysiology and the development of new therapies for cGvHD. While our field has historically approached treatment from an empiric position, research performed at the bedside and bench has elucidated some of the complex pathophysiology of cGvHD. From the clinical perspective, there is significant variability of disease manifestations between individual patients, pointing to diverse biological underpinnings. Capitalizing on progress made to date, the field is now focused on establishing personalized treatment approaches. The manuscript's intent is to concisely review recent knowledge gained and formulate a path towards patient-specific cGvHD therapy.
Keyphrases
- hematopoietic stem cell
- healthcare
- end stage renal disease
- bone marrow
- type diabetes
- stem cells
- stem cell transplantation
- allogeneic hematopoietic stem cell transplantation
- cardiovascular disease
- coronary artery disease
- prognostic factors
- risk factors
- high dose
- peritoneal dialysis
- drug induced
- cell therapy
- clinical practice
- free survival
- urinary tract infection